Literature DB >> 20674882

Prevalence of high-risk indications for influenza vaccine varies by age, race, and income.

Richard K Zimmerman1, Diane S Lauderdale, Sylvia M Tan, Diane K Wagener.   

Abstract

Estimates of the proportions of the population who are at high risk of influenza complications because of prior health status or who are likely to have decreased vaccination response because of immunocompromising conditions would enhance public health planning and model-based projections. We estimate these proportions and how they vary by population subgroups using national data systems for 2006-2008. The proportion of individuals at increased risk of influenza complications because of health conditions varied 10-fold by age (4.2% of children <2 years to 47% of individuals >64 years). Age-specific prevalence differed substantially by gender, by racial/ethnic groups (with African Americans highest in all age groups) and by income. Individuals living in families with less than 200% of federal poverty level (FPL) were significantly more likely to have at least one of these health conditions, compared to individuals with 400% FPL or more (3-fold greater among <2 and 30% greater among >64 years). Among children, there were significantly elevated proportions in all regions compared to the West. The estimated prevalence of immunocompromising conditions ranged from 0.02% in young children to 6.14% older adults. However, national data on race/ethnicity and income are not available for most immunocompromising conditions, nor is it possible to fully identify the degree of overlap between persons with high-risk health conditions and with immunocompromising conditions. Modifications to current national data collection systems would enhance the value of these data for public health programs and influenza modeling.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20674882      PMCID: PMC2939262          DOI: 10.1016/j.vaccine.2010.07.037

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  29 in total

1.  Optimizing influenza vaccine distribution.

Authors:  Jan Medlock; Alison P Galvani
Journal:  Science       Date:  2009-08-20       Impact factor: 47.728

2.  Protection of racial/ethnic minority populations during an influenza pandemic.

Authors:  Sonja S Hutchins; Kevin Fiscella; Robert S Levine; Danielle C Ompad; Marian McDonald
Journal:  Am J Public Health       Date:  2009-10       Impact factor: 9.308

3.  Influenza in hospitalized adults: gaining insight into a significant problem.

Authors:  Michael G Ison
Journal:  J Infect Dis       Date:  2009-08-15       Impact factor: 5.226

4.  Interim results: state-specific influenza A (H1N1) 2009 monovalent vaccination coverage - United States, October 2009-January 2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-04-02       Impact factor: 17.586

5.  Intervention strategies for an influenza pandemic taking into account secondary bacterial infections.

Authors:  Andreas Handel; Ira M Longini; Rustom Antia
Journal:  Epidemics       Date:  2009-09       Impact factor: 4.396

6.  Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2009-08-28

7.  H1N1 2009 influenza virus infection during pregnancy in the USA.

Authors:  Denise J Jamieson; Margaret A Honein; Sonja A Rasmussen; Jennifer L Williams; David L Swerdlow; Matthew S Biggerstaff; Stephen Lindstrom; Janice K Louie; Cara M Christ; Susan R Bohm; Vincent P Fonseca; Kathleen A Ritger; Daniel J Kuhles; Paula Eggers; Hollianne Bruce; Heidi A Davidson; Emily Lutterloh; Meghan L Harris; Colleen Burke; Noelle Cocoros; Lyn Finelli; Kitty F MacFarlane; Bo Shu; Sonja J Olsen
Journal:  Lancet       Date:  2009-07-28       Impact factor: 79.321

8.  Distribution of vaccine/antivirals and the 'least spread line' in a stratified population.

Authors:  E Goldstein; A Apolloni; B Lewis; J C Miller; M Macauley; S Eubank; M Lipsitch; J Wallinga
Journal:  J R Soc Interface       Date:  2009-10-14       Impact factor: 4.118

9.  Viral loads and duration of viral shedding in adult patients hospitalized with influenza.

Authors:  Nelson Lee; Paul K S Chan; David S C Hui; Timothy H Rainer; Eric Wong; Kin-Wing Choi; Grace C Y Lui; Bonnie C K Wong; Rita Y K Wong; Wai-Yip Lam; Ida M T Chu; Raymond W M Lai; Clive S Cockram; Joseph J Y Sung
Journal:  J Infect Dis       Date:  2009-08-15       Impact factor: 5.226

10.  Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States.

Authors:  Nicole E Basta; Dennis L Chao; M Elizabeth Halloran; Laura Matrajt; Ira M Longini
Journal:  Am J Epidemiol       Date:  2009-08-13       Impact factor: 4.897

View more
  26 in total

Review 1.  Aging, cytomegalovirus (CMV) and influenza vaccine responses.

Authors:  Daniela Frasca; Bonnie B Blomberg
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

2.  Improving the evidence base for decision making during a pandemic: the example of 2009 influenza A/H1N1.

Authors:  Marc Lipsitch; Lyn Finelli; Richard T Heffernan; Gabriel M Leung; Stephen C Redd
Journal:  Biosecur Bioterror       Date:  2011-06

3.  Racial Disparities in Adult Pneumococcal Vaccination Indications and Pneumococcal Hospitalizations in the U.S.

Authors:  Mary Patricia Nowalk; Angela R Wateska; Chyongchiou Jeng Lin; William Schaffner; Lee H Harrison; Richard K Zimmerman; Kenneth J Smith
Journal:  J Natl Med Assoc       Date:  2019-06-03       Impact factor: 1.798

4.  Does Choice of Influenza Vaccine Type Change Disease Burden and Cost-Effectiveness in the United States? An Agent-Based Modeling Study.

Authors:  Jay V DePasse; Kenneth J Smith; Jonathan M Raviotta; Eunha Shim; Mary Patricia Nowalk; Richard K Zimmerman; Shawn T Brown
Journal:  Am J Epidemiol       Date:  2017-05-01       Impact factor: 4.897

5.  Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations.

Authors:  Angela R Wateska; Mary Patricia Nowalk; Chyongchiou J Lin; Lee H Harrison; William Schaffner; Richard K Zimmerman; Kenneth J Smith
Journal:  Am J Prev Med       Date:  2020-01-28       Impact factor: 5.043

6.  High TNF-α levels in resting B cells negatively correlate with their response.

Authors:  Daniela Frasca; Alain Diaz; Maria Romero; Ana Marie Landin; Bonnie B Blomberg
Journal:  Exp Gerontol       Date:  2014-01-15       Impact factor: 4.032

7.  Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64 years compared to the US general population.

Authors:  Angela R Wateska; Mary Patricia Nowalk; Chyongchiou J Lin; Lee H Harrison; William Schaffner; Richard K Zimmerman; Kenneth J Smith
Journal:  Vaccine       Date:  2019-03-04       Impact factor: 3.641

8.  The benefits to all of ensuring equal and timely access to influenza vaccines in poor communities.

Authors:  Bruce Y Lee; Shawn T Brown; Rachel R Bailey; Richard K Zimmerman; Margaret A Potter; Sarah M McGlone; Philip C Cooley; John J Grefenstette; Shanta M Zimmer; William D Wheaton; Sandra Crouse Quinn; Ronald E Voorhees; Donald S Burke
Journal:  Health Aff (Millwood)       Date:  2011-06       Impact factor: 6.301

9.  Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination.

Authors:  Dimitrios G Koutsonanos; Maria del Pilar Martin; Vladimir G Zarnitsyn; Joshy Jacob; Mark R Prausnitz; Richard W Compans; Ioanna Skountzou
Journal:  J Infect Dis       Date:  2011-06-17       Impact factor: 5.226

10.  Optimal targeting of seasonal influenza vaccination toward younger ages is robust to parameter uncertainty.

Authors:  Martial L Ndeffo Mbah; Jan Medlock; Lauren Ancel Meyers; Alison P Galvani; Jeffrey P Townsend
Journal:  Vaccine       Date:  2013-05-16       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.